INVITED SPEAKER

Doctor Allan Saul

Dr Saul has a PhD in Biochemistry from the University of Queensland and has more than 40 years of working in vaccine development, especially for vaccines for high-impact Developing World applications. These include vaccines to prevent diseases caused by Plasmodium falciparum and P. vivax, Salmonella (Typhi, Paratyphi A and invasive nontyphoidal Salmonella), Shigella, Group A Streptococcus. He worked for nearly 20 years at the Queensland Institute for Medical Research, was a co-Branch Chief at the NIH Malaria Vaccine Development Branch in Maryland, USA and more recently was the Institute Director of the GSK Vaccines Institute for Global Health (GVGH) in Siena, Italy. He played a pivotal role in many vaccine development projects from inception, through production of clinical grade material and through many clinical trials done under oversight from the TGA, FDA, various European Regulatory Agencies, and Regulatory Agencies in Africa, and Asia. The most developed GVGH vaccine (a new generation Typhoid conjugate vaccine) was licensed to an Indian manufacturer, is registered for sale and received WHO pre-qualification. With this background, he brings a unique perspective to vaccine development spanning Academia, NIH, developing country vaccine manufacturers and big Pharma.

He retired in December 2019 and moved to Canberra, Australia. He is on the advisory boards of multiple vaccine projects and Funding organizations including the Australian Strep A Vaccine Initiative, Rapua te mea ngaro ka tau in New Zealand and the Vaccine Advisory Committee of the Leducq Foundation.

Dr Saul is an Honorary Senior Principal Research Fellow at the Burnet Institute and an Honorary Professor in the Department of Microbiology and Immunology at the University of Melbourne. He has published over 290 peer-reviewed papers and is an inventor on 17 families of granted patents.